📌 Key Takeaways
- On August 20, 2026, South Korea’s National Assembly passed three separate pieces of legislation simultaneously:
a new K-beauty Promotion Act, an amendment to the Cosmetics Act,
and an amendment to the Medical Device Act. - The Cosmetics Act amendment establishes a national master plan
and a new Cosmetics Management Council—
running in parallel with the promotion law to systematize safety oversight. - The Medical Device Act amendment mandates enhanced online ad monitoring
and requires platform operators (information and communications service providers)
to take necessary measures against non-compliant content. - A separate draft amendment to the Cosmetics Act Enforcement Rules (published July 2026)
proposes banning AI-generated fake-expert advertisements—
a provision still under review and not yet confirmed in final enacted text.
The headline on August 20, 2026 was South Korea’s landmark K-beauty Promotion Act—
the country’s first dedicated legislation to nurture its cosmetics industry as a strategic export sector.
But on the same day, two other bills quietly passed the National Assembly floor vote:
an amendment to the Cosmetics Act and an amendment to the Medical Device Act.
The simultaneous passage of all three was not coincidental.
South Korea is running a dual-track policy: grow the industry, and hold it accountable at the same time.
NERO breaks down what each law actually does—
and what the combined signal means for the global aesthetic medicine and beauty device market.
INDEX
Three Laws, One Day: What Passed on August 20, 2026
The three bills are legally distinct and serve different functions.
Reading them together reveals the policy architecture—
not just individual regulatory changes.
① K-beauty Promotion Act (New Law)
South Korea’s first standalone legislation dedicated to cosmetics industry development.
Key pillars include: a five-year comprehensive national plan,
designation of “innovative enterprise” status for qualifying companies,
support for AI, data, and digital technology integration,
and preferential treatment for small and mid-sized businesses.
The Ministry of Health and Welfare (MOHW) leads implementation.
This law takes effect one year after promulgation (confirmed).
NERO covers this law in a separate dedicated article.
② Cosmetics Act Amendment — Safety Management and Governance
This is the safety-side counterpart to the Promotion Act.
The amendment introduces two structural additions:
a national Cosmetics Management Master Plan (마스터플랜)
and a new Cosmetics Management Council.
The goal is to systematize policy operations and strengthen the international competitiveness of K-beauty—
not through deregulation, but through structured governance.
(Source: ChemLinked, September 2, 2026)
The precise enforcement date for this amendment should be confirmed
against the official promulgation notice and subordinate regulations.
③ Medical Device Act Amendment — Online Ad Monitoring and Platform Accountability
This amendment targets the online advertising ecosystem for medical devices.
Two confirmed provisions:
① Enhanced monitoring of online medical device labeling and advertising.
② Mandatory measures required of information and communications service providers (i.e., platform operators).
In practical terms, platforms hosting non-compliant medical device ads
can now be required to act—not just the advertisers themselves.
(Source: KDI Policy Data, confirmed)
For full statutory text, verification against MFDS official publications is recommended.
The AI Fake-Expert Ad Ban: What Is Actually Confirmed
Separate from the August 20 Medical Device Act amendment,
a draft revision to the Cosmetics Act Enforcement Rules was published for public comment in July 2026.
This draft attracted significant industry attention for one specific provision:
a proposed ban on AI-generated fake-expert advertisements.
The AI fake-expert ad ban is a draft proposal—not confirmed enacted law.
It appeared in a July 8, 2026 draft amendment to the Cosmetics Act Enforcement Rules,
reported by Cleo Labs on July 27, 2026.
It has not been verified as final statutory text in the August 20 enacted legislation
through primary sources (KDI policy data, MFDS official publications).
Verification against MFDS official documents is strongly recommended.
The scenario being regulated is concrete and already widespread:
“An AI-generated physician face recommends a product in a social media video—
the physician does not exist.”
Whether or not the specific provision is enacted in its current form,
the regulatory direction is clear.
South Korea is moving toward legal frameworks that explicitly address AI-generated content in beauty and medical advertising.
This is a policy trajectory that markets worldwide—including Japan and the United States—
will need to engage with.
“Grow the Industry, Hold It Accountable”: What the Dual-Track Signals
The structural logic of South Korea’s August 20 legislative package is straightforward:
promotion and accountability are not opposites—they are designed to run in parallel.
This is a meaningful departure from the regulatory framing common in many markets,
where industry development and consumer protection are treated as competing priorities.
① For clinics importing or using Korean-origin devices and products:
South Korea’s tightening standards signal a directional shift toward higher safety baselines.
Confirming approval and notification status under each country’s own regulatory framework
(e.g., Japan’s PMDA, U.S. FDA) remains essential—
regardless of Korean MFDS clearance status.
② For clinics and brands running SNS and online advertising:
AI-generated expert content is now a live regulatory issue in a major K-beauty market.
Alignment with applicable advertising guidelines in each operating jurisdiction
is increasingly important—not just a compliance formality.
③ For cross-border device and product distribution:
“Approved in Korea” does not mean “safe or legal in your market.”
Each country maintains its own review and approval architecture.
Understanding those distinctions is a baseline requirement for responsible sourcing.
“K-beauty exports hit $11.4 billion” is one story.
“Online ad monitoring strengthened, AI fake-expert ads targeted” is another.
But the fact that both moved on the same day is the real story.
South Korea is building the infrastructure to grow an industry
and hold it accountable—simultaneously.
That is the architecture worth watching.
Japan’s medical advertising guidelines cover aesthetic clinics,
but explicit regulatory treatment of AI-generated content
remains underdeveloped as of 2026.
South Korea establishing a framework that places obligations on platforms—
not just advertisers—is a structural precedent.
It is a debate Japan will need to have.
NERO will continue tracking this closely.
Summary
- On August 20, 2026, South Korea’s National Assembly passed three bills:
① the K-beauty Promotion Act (new law, industry development),
② the Cosmetics Act Amendment (safety management, master plan, management council),
③ the Medical Device Act Amendment (online ad monitoring, platform operator obligations).
The Promotion Act takes effect one year after promulgation (confirmed).
Enforcement dates for the two amendments should be verified against official promulgation notices. - The Cosmetics Act Amendment introduces a national master plan and a Cosmetics Management Council,
systematizing safety governance in parallel with the promotion framework.
The Medical Device Act Amendment mandates enhanced monitoring of online medical device advertising
and requires platform operators to take necessary measures against non-compliant content.
(Sources: ChemLinked, KDI Policy Data) - A separate draft revision to the Cosmetics Act Enforcement Rules (published July 8, 2026)
proposes banning AI-generated fake-expert advertisements.
This remains a draft proposal—final statutory text requires verification via MFDS official publications.
The direction of travel toward AI content regulation in beauty advertising is clear regardless. - South Korea’s dual-track design—promotion alongside accountability—
carries direct implications for how global markets handle Korean-origin products,
online advertising standards, and cross-border device distribution.
“Approved in Korea” is not a substitute for regulatory clearance in each operating market.
R&D support, innovative enterprise designation, and five-year national planning.
The Cosmetics Act Amendment modifies existing law governing safety management, quality, labeling, and advertising—
introducing a national master plan and a new management council to systematize oversight.
In short: the Promotion Act grows the industry; the Cosmetics Act Amendment governs how it operates safely.
South Korea is advancing both simultaneously, rather than treating them as competing priorities.
The provision appeared in a draft amendment to the Cosmetics Act Enforcement Rules
published for public comment on July 8, 2026, and reported by Cleo Labs on July 27, 2026.
It has not been verified as final statutory text in the August 20 enacted legislation
through primary sources.
Verification against MFDS official publications is recommended before drawing compliance conclusions.
Each country maintains its own regulatory review and approval architecture.
MFDS clearance in South Korea does not constitute approval under Japan’s PMDA,
the U.S. FDA, or the EU’s regulatory frameworks.
Clinics and distributors operating outside Korea must confirm compliance
with the applicable national regulatory requirements in each market independently.
Sources:
1. KDI (Korea Development Institute) Policy Data. List of bills passed by the National Assembly on August 20, 2026 (Medical Device Act Amendment, Cosmetics Act Amendment — primary source). eiec.kdi.re.kr
2. Ministry of Health and Welfare, Republic of Korea (MOHW). Official announcement: 화장품산업 육성 및 지원에 관한 법률 (August 20, 2026). mohw.go.kr
3. ChemLinked. “South Korea Passes the Cosmetic Industry Promotion Act and Amendments to the Cosmetics Act.” September 2, 2026. cosmetic.chemlinked.com
4. Cleo Labs. “Korea cosmetics safety assessment 2026 – the AI fake-expert ad ban buried in the same text.” July 27, 2026. cleolabs.co
5. CIRS Group. “South Korea Strengthens Oversight of Directly Purchased Overseas Cosmetics.” April 8, 2026. cirs-group.com
